Lithera beta agonist begins trial as fat-buster

03/19/2013 | Xconomy

Lithera announced the launch of a 500-patient, Phase II trial of an injectable version of salmeterol xinafoate for localized reduction of abdominal fat tissue. The selective beta agonist is approved in aerosol form as an inhaled asthma treatment.

View Full Article in:

Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC